Clinical, pathological characteristics and long-term outcomes of hepatitis B virus related cirrhosis in pediatric observational study

Table 2 Antiviral response of pediatric liver cirrhosis, median (interquartile range)/n (%)/mean ± SD

Variable	Total (N = 46)
Demographics
Age (years)	8 (3.5-13)
Male	38 (82.6)
Female	8 (17.4)
BMI (kg/m2)	16.38 (15.3-18.15)
Antiviral regimen
NA	5 (10.8)
NA-HBV DNA loss	4 (80)
NA-HBV DNA loss time (months)	14.93 (4.99-54.47)
IFN + NA	41 (89.2)
IFN + NA HBsAg loss	8 (20)
IFN + NA HBeAg loss	26 (65)
IFN + NA HBV DNA loss	38 (95)
IFN + NA HBsAg loss time (months)	35.17 ± 21.51
IFN + NA HBeAg loss time (months)	10.54 (3.52-37.87)
IFN + NA HBV DNA loss time (months)	7.77 (5.22-14.41)
LC resolution at EOT
HBsAg loss	8 (17.4)
HBeAg loss	26 (56.5)
HBV DNA loss	42 (91.3)
HBsAg loss time (months)	35.17 ± 21.51
HBeAg loss time (months)	42.14 (14.07-151.46)
HBV DNA loss time (months)	7.77 (4.79-14.46)

BMI: Body mass index; NA: Nucleoside analogue; HBV: Hepatitis B virus; IFN: Interferon; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; LC: Liver cirrhosis; EOT: End of treatment.